CN110913858B - 激酶抑制剂及其用途 - Google Patents
激酶抑制剂及其用途 Download PDFInfo
- Publication number
- CN110913858B CN110913858B CN201880047293.5A CN201880047293A CN110913858B CN 110913858 B CN110913858 B CN 110913858B CN 201880047293 A CN201880047293 A CN 201880047293A CN 110913858 B CN110913858 B CN 110913858B
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- formula
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411240964.3A CN119264073A (zh) | 2017-05-17 | 2018-05-17 | 激酶抑制剂及其用途 |
| CN202411240962.4A CN119285572A (zh) | 2017-05-17 | 2018-05-17 | 激酶抑制剂及其用途 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507698P | 2017-05-17 | 2017-05-17 | |
| US62/507,698 | 2017-05-17 | ||
| US201862664895P | 2018-04-30 | 2018-04-30 | |
| US62/664,895 | 2018-04-30 | ||
| PCT/US2018/033266 WO2018213632A1 (en) | 2017-05-17 | 2018-05-17 | Kinase inhibitors and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411240964.3A Division CN119264073A (zh) | 2017-05-17 | 2018-05-17 | 激酶抑制剂及其用途 |
| CN202411240962.4A Division CN119285572A (zh) | 2017-05-17 | 2018-05-17 | 激酶抑制剂及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110913858A CN110913858A (zh) | 2020-03-24 |
| CN110913858B true CN110913858B (zh) | 2024-09-24 |
Family
ID=64274744
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411240964.3A Pending CN119264073A (zh) | 2017-05-17 | 2018-05-17 | 激酶抑制剂及其用途 |
| CN201880047293.5A Active CN110913858B (zh) | 2017-05-17 | 2018-05-17 | 激酶抑制剂及其用途 |
| CN202411240962.4A Pending CN119285572A (zh) | 2017-05-17 | 2018-05-17 | 激酶抑制剂及其用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411240964.3A Pending CN119264073A (zh) | 2017-05-17 | 2018-05-17 | 激酶抑制剂及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411240962.4A Pending CN119285572A (zh) | 2017-05-17 | 2018-05-17 | 激酶抑制剂及其用途 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11203600B2 (enExample) |
| EP (1) | EP3624797A4 (enExample) |
| JP (2) | JP7064512B2 (enExample) |
| KR (1) | KR102638151B1 (enExample) |
| CN (3) | CN119264073A (enExample) |
| AU (1) | AU2018269743B2 (enExample) |
| BR (1) | BR112019023918A2 (enExample) |
| CA (1) | CA3063934A1 (enExample) |
| CL (1) | CL2019003263A1 (enExample) |
| CO (1) | CO2019012957A2 (enExample) |
| CR (1) | CR20190566A (enExample) |
| DO (1) | DOP2019000290A (enExample) |
| EC (1) | ECSP19089214A (enExample) |
| IL (1) | IL270648B2 (enExample) |
| MX (2) | MX2019013645A (enExample) |
| MY (1) | MY200328A (enExample) |
| PE (2) | PE20241932A1 (enExample) |
| PH (1) | PH12019550235A1 (enExample) |
| SG (1) | SG10201913927VA (enExample) |
| TW (1) | TWI794232B (enExample) |
| WO (1) | WO2018213632A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7273954B2 (ja) * | 2018-10-19 | 2023-05-15 | ディスアーム セラピューティクス， インコーポレイテッド | Ｎａｄ＋またはｎａｄ＋前駆体と組み合わせたｓａｒｍ１の阻害 |
| IL291665B2 (en) * | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| TW202535863A (zh) * | 2020-02-13 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| WO2021187605A1 (ja) * | 2020-03-19 | 2021-09-23 | 田辺三菱製薬株式会社 | 含窒素複素環αシアノカルボニル化合物 |
| TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| KR200493347Y1 (ko) | 2020-07-06 | 2021-03-17 | 박혜진 | 휴대가 용이한 마스크 |
| US20240327412A1 (en) * | 2021-02-19 | 2024-10-03 | Kalvista Pharmaceuticals Limited | Factor xiia inhibitors |
| US20240208986A1 (en) * | 2021-04-27 | 2024-06-27 | Merck Sharp & Dohme Llc | Phenyl azepines as ripk1 inhibitors and methods of use thereof |
| EP4329766A4 (en) * | 2021-04-27 | 2025-06-11 | Merck Sharp & Dohme LLC | RIPK1 INHIBITORS AND METHODS OF USE |
| WO2023083847A1 (en) | 2021-11-11 | 2023-05-19 | Sanofi | Isoxazolidines as ripk1 inhibitors and use thereof |
| TW202417453A (zh) * | 2022-07-25 | 2024-05-01 | 美商戴納立製藥公司 | ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶並［３，４－ｆ］［１，４］氧氮呯－９－甲腈的固體形式 |
| WO2024044151A1 (en) * | 2022-08-23 | 2024-02-29 | Genzyme Corporation | Methods for treating receptor-interacting protein kinase 1-mediated diseases |
| TW202444357A (zh) * | 2023-01-23 | 2024-11-16 | 美商健臻公司 | ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶并［３，４－ｆ］［１，４］氧氮呯－９－甲腈之藥品調配物 |
| TW202515552A (zh) * | 2023-06-27 | 2025-04-16 | 美商健臻公司 | 製備4-(3,3-二氟-2,2-二甲基-丙醯基)-3,5-二氫-2h-吡啶并[3,4-f][1,4]氧雜氮呯-9-腈之方法 |
| CN120365288A (zh) * | 2024-01-23 | 2025-07-25 | 南京天印健华医药科技有限公司 | 作为ripk1抑制剂的杂环化合物 |
| CN120365287A (zh) * | 2024-01-23 | 2025-07-25 | 南京天印健华医药科技有限公司 | 作为ripk1抑制剂的杂环化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3861187B2 (ja) * | 1996-08-02 | 2006-12-20 | 住友精化株式会社 | チアゼピン誘導体の製造方法 |
| MXPA03002649A (es) | 2000-09-27 | 2003-09-25 | Ajinomoto Kk | Derivado de benzodiazepina. |
| RU2456287C1 (ru) * | 2011-05-20 | 2012-07-20 | Николай Филиппович Савчук | Стимуляторы секреции инкретиновых гормонов, способы их получения и применения |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| CN104059068B (zh) | 2013-03-20 | 2017-02-08 | 中国科学院上海药物研究所 | β‑氨基羰基类化合物、其制备方法、药物组合物及其用途 |
| CN107801396B (zh) * | 2015-02-02 | 2021-10-22 | 福马治疗股份有限公司 | 作为hdac抑制剂的3-芳基-4-酰氨基-二环[4,5,0]异羟肟酸 |
| UY36680A (es) * | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| PH12017502255B1 (en) * | 2015-06-15 | 2022-07-22 | Astex Therapeutics Ltd | Nrf2 regulators |
-
2018
- 2018-05-17 JP JP2019563596A patent/JP7064512B2/ja active Active
- 2018-05-17 SG SG10201913927VA patent/SG10201913927VA/en unknown
- 2018-05-17 PE PE2024000411A patent/PE20241932A1/es unknown
- 2018-05-17 CA CA3063934A patent/CA3063934A1/en active Pending
- 2018-05-17 CN CN202411240964.3A patent/CN119264073A/zh active Pending
- 2018-05-17 TW TW107116834A patent/TWI794232B/zh active
- 2018-05-17 CN CN201880047293.5A patent/CN110913858B/zh active Active
- 2018-05-17 KR KR1020197036911A patent/KR102638151B1/ko active Active
- 2018-05-17 IL IL270648A patent/IL270648B2/en unknown
- 2018-05-17 AU AU2018269743A patent/AU2018269743B2/en active Active
- 2018-05-17 PE PE2019002424A patent/PE20200729A1/es unknown
- 2018-05-17 CR CR20190566A patent/CR20190566A/es unknown
- 2018-05-17 BR BR112019023918-9A patent/BR112019023918A2/pt not_active Application Discontinuation
- 2018-05-17 MX MX2019013645A patent/MX2019013645A/es unknown
- 2018-05-17 CN CN202411240962.4A patent/CN119285572A/zh active Pending
- 2018-05-17 WO PCT/US2018/033266 patent/WO2018213632A1/en not_active Ceased
- 2018-05-17 EP EP18802127.3A patent/EP3624797A4/en active Pending
- 2018-05-17 MY MYPI2019006664A patent/MY200328A/en unknown
-
2019
- 2019-11-13 PH PH12019550235A patent/PH12019550235A1/en unknown
- 2019-11-14 CL CL2019003263A patent/CL2019003263A1/es unknown
- 2019-11-14 DO DO2019000290A patent/DOP2019000290A/es unknown
- 2019-11-14 US US16/684,340 patent/US11203600B2/en active Active
- 2019-11-14 MX MX2022010755A patent/MX2022010755A/es unknown
- 2019-11-19 CO CONC2019/0012957A patent/CO2019012957A2/es unknown
- 2019-12-16 EC ECSENADI201989214A patent/ECSP19089214A/es unknown
-
2021
- 2021-09-09 JP JP2021146775A patent/JP7241825B2/ja active Active
- 2021-10-26 US US17/511,193 patent/US12129263B2/en active Active
-
2024
- 2024-09-18 US US18/889,058 patent/US20250011338A1/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 1920040-60-3;STN;《STN网络公开》;20160529;第1页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110913858B (zh) | 激酶抑制剂及其用途 | |
| US12247026B2 (en) | Heterocyclic compounds as immunomodulators | |
| CN113272303B (zh) | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 | |
| TWI378101B (en) | Pyridine derivatives and their use in the treatment of psychotic disorders | |
| CN104884458B (zh) | 作为蛋白质激酶抑制剂的稠合杂环化合物 | |
| CN104470924B (zh) | 作为tnf活性调节剂的咪唑并吡嗪衍生物 | |
| WO2021219072A1 (zh) | 作为kras抑制剂的杂环化合物的制备及其应用方法 | |
| AU2016280137B2 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| CN104470925A (zh) | 作为激酶抑制剂的咪唑并三嗪甲腈 | |
| TW201506018A (zh) | 二雜芳基化合物及其用途 | |
| EP3166608A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| CN117917410A (zh) | pan-KRAS降解剂及其制备方法和应用 | |
| WO2022247816A1 (zh) | 含氮杂环类化合物、其制备方法及其在医药上的应用 | |
| JP2021504380A (ja) | Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物 | |
| CN106061980A (zh) | 作为mknk1和mknk2抑制剂的噻吩并嘧啶 | |
| KR20230123471A (ko) | 화합물, 조성물 및 방법 | |
| WO2024217348A1 (zh) | Kif18a抑制剂及其制备方法和用途 | |
| WO2025232650A1 (zh) | Kif18a抑制剂及其制备方法和用途 | |
| KR20250117453A (ko) | 3-플루오로-4-하이드록시벤즈아미드-함유 억제제 및/또는 분해제 및 이의 용도 | |
| CN101434604A (zh) | 稠合的n-杂环化合物和它们作为crf受体拮抗剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TG01 | Patent term adjustment | ||
| TG01 | Patent term adjustment |